United Therapeutics Corp - Company Profile
Powered by 
All the data and insights you need on United Therapeutics Corp in one report.
$295
- Save hours of research time and resources with
our up-to-date United Therapeutics Corp Strategy Report
- Understand United Therapeutics Corp position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
United Therapeutics Corp (UTC) develops and commercializes drugs to address unmet medical needs in chronic and life-threatening ailments including pulmonary arterial hypertension (PAH), cancer and infectious diseases.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
R&D efforts focus on developing and advancing the compounds in its pipeline that include new indications, formulations, and delivery devices for its existing products, besides new products to treat PAH, pulmonary fibrosis, and other conditions. It is also developing an implantable system for Remodulin and the RemUnity system for the delivery of intravenous and subcutaneous Remodulin, respectively. The company’s pipeline include RemoPro (subcutaneous prodrug) for PAH is in Phase I clinical trials, Tyvaso( treprostinil) for IPF in Phase 3 TETON studies, Ralinepag (IP receptor agonist) is in Phase 3 ADVANCE studies. The company owns various patents for its products such as Tyvaso, Tyvaso DPI, Remodulin, and Orenitram from 2023 to 2028. The company maintains Orange Book for the record of approval of a drug through an NDA or upon issuance of new patents. The company focuses on expanding the use of Tyvaso to treat pulmonary hypertension in certain categories of WHO Group 3. In FY2022 it spent US$322.9 million on its R&D, which as a percentage of revenue stood at 16.7%.
Product Categories
- Adcirca (tadalafil)
- Orenitram (treprostinil)
- Other
- Remodulin (treprostinil)
- Tyvaso (treprostinil)
- Unituxin (dinutuximab)
Overview
It is a PDE-5 inhibitor, an oral therapy to treat pulmonary arterial hypertension (PAH). Tadalafil is also the active pharmaceutical ingredient in Cialis, which is marketed by Lilly for the treatment of erectile dysfunction.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It is an extended-release tablet used for the treatment of PAH. It is an FDA-approved, orally administered prostacyclin analogue.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It is a prostacyclin vasodilator to treat pulmonary arterial hypertension (PAH). Remodulin (treprostinil) injection is FDA approved for intravenous use for treating patients requiring transition from Flolan (epoprostenol). The company sells Remodulin in Japan under the brand name Treprost.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It is an inhaled prostacyclin therapy to treat PAH. It contains active ingredient treprostinil, which is administered four times a day by inhaling nine breaths during each treatment session.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
It is used for the treatment of pediatric patients with high-risk neuroblastoma (pediatric cancer) who respond at least partially to prior first-line multiagent, multimodality therapy.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Geographical Segments
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer